Mycoril Spray

Quick links to important sections

Mycoril Spray

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mycoril Spray

Property Description
Active ingredient Clotrimazole
Form Topical Solution (Spray)
Pharmacological class Azole Antifungal (Antimycotic)
General purpose Controlling fungal and yeast infections
Origin Synthetic

Identity and Pharmacological Classification

Mycoril Spray is a pharmaceutical preparation classified as an antifungal medication, specifically formulated for topical administration on the skin. Its active component is Clotrimazole, a substance that is clinically recognized for its efficacy against a wide array of fungal organisms. Clotrimazole is a synthetic entity derived from the Imidazole family, placing it within the broader Azole Antifungal class. This classification establishes the drug as an antimycotic agent, signifying its specific purpose: to inhibit the growth and proliferation of the fungi and yeasts responsible for superficial skin conditions.

Composition and the Topical Spray Form

The product is a single-ingredient preparation presented as a topical solution spray. In this formulation, Clotrimazole is dissolved within a specific liquid vehicle, typically a hydroalcoholic solvent or similar solution base. The spray delivery method facilitates hygienic, non-contact application over affected areas, which is especially advantageous for covering large or difficult-to-reach parts of the body. By remaining localized to the skin's surface, the topical route ensures the medication's action is concentrated at the infection site, minimizing systemic absorption.

General Purpose of an Azole Antifungal

The general purpose of Mycoril Spray is to control, eliminate, and resolve fungal and yeast infections by directly interfering with the causative organisms. The Clotrimazole component exerts its effect by specifically damaging the permeability barrier of the fungal cytoplasmic membrane. This fundamental action against the fungal cell structure is how the Azole class of drugs functions to alleviate the discomfort associated with the underlying fungal infections.

Regulatory References

  1. Topical Drug Delivery
  2. Azole Antifungal Mechanism of Action

What side effects are possible with Mycoril Spray?

Possible Side Effects and Safety Information

The safety profile of Mycoril Spray (Clotrimazole Topical Solution) is characterized primarily by localized reactions at the application site, as documented in official regulatory materials. The systemic absorption of the active ingredient, Clotrimazole, following topical administration is generally noted as minimal.

Adverse Reaction Classifications

Adverse reactions are officially classified by frequency, with the most common effects typically involving the skin and subcutaneous tissue system.

  • Common Reactions: The most frequently reported experiences are associated with the site of application and include sensations of stinging, burning, pain, erythema (redness), and general skin irritation.
  • Rare Reactions: Regulatory documents list the potential for rare, serious systemic events involving the immune system. These include hypersensitivity, angioedema, and anaphylactic reactions.

Regulatory Safety Considerations

The official labeling includes specific safety considerations for certain patient populations and situations, reflecting the formal constraints of use.

  • Hypersensitivity: The product is contraindicated in individuals with a known allergy or hypersensitivity to Clotrimazole or any other component of the formulation.
  • Application Avoidance: The topical solution is not to be used for ophthalmic purposes, and contact with the eyes should be avoided.
  • Pregnancy and Lactation: Due to the lack of extensive safety data, caution is advised, particularly during the first trimester of pregnancy. For nursing patients, the excretion of the substance into human milk is unknown, requiring consideration.

Overall Safety Profile

The regulatory safety structure defines the risks as predominantly local and common, contrasting with the rare but serious potential for systemic allergic responses.

Overdose and Emergency Response

Overdose and When to Seek Help: Mycoril Spray

Official regulatory information indicates that a risk of acute intoxication is not generally anticipated following a single topical application, even if applied over a large area. The primary regulatory focus for overdose concerns centers on cases of inadvertent oral ingestion.


Documented Manifestations Following Oral Ingestion

Symptoms that have been associated with accidental oral ingestion, and which signal the need for medical evaluation, include:

  • Nausea and Vomiting
  • Dizziness

Emergency Action and Management

Situation
If signs of allergic reaction occur (e.g., swelling of the lips/face/throat, difficulty breathing, syncope, or low blood pressure), immediate emergency medical attention is required.
If accidental oral ingestion is suspected and symptoms (such as dizziness or vomiting) become apparent, contact emergency medical services or a poison control center.
Antidote Status
There is no specific antidote for Mycoril Spray listed in official regulatory documentation. Management is supportive.
Procedural Notes
If gastric lavage is considered following oral ingestion, official guidance states this should only be performed if clinical symptoms are apparent and provided the patient's airway is adequately protected.

Therapeutic Uses of Mycoril Spray

What Mycoril Spray Treats: Main Uses and Benefits

Mycoril Spray is commonly used across therapeutic domains involving symptoms related to inflammatory or irritative states caused by superficial fungal infections. It is considered relevant for conditions where discomfort may interfere with daily functioning. The medication is commonly used to treat fungal skin conditions that interfere with daily comfort.

The medication plays a role in managing acute or recurrent episodes of common conditions like Athlete's foot (Tinea pedis), Jock itch (Tinea cruris), Ringworm (Tinea corporis), cutaneous candidiasis, and Tinea versicolor. It is applied in addressing symptoms related to physical discomfort, particularly the intense itching (pruritus), burning sensation, and soreness often linked to these rashes.

“The medication supports the patient during symptomatic periods by easing distress and is used across domains where additional symptomatic support is needed.”

This therapeutic focus contributes to improved comfort during periods of heightened symptoms. Mycoril Spray is relevant for conditions characterized by redness, scaling, flaking, and cracking of the skin, particularly those affecting warm, moist folds of the body (e.g., fungal intertrigo). In conditions involving pathogenic growth, the medication may assist in managing related symptomatic manifestations.

Quick Fact: Relief for Pruritus The spray is commonly used to help with acute sensory symptoms, providing supportive relief when itching and burning interfere with routine activities.

Regulatory References

  1. MedlinePlus Drug Information on Clotrimazole Topical

Eligibility and Restrictions for Use

Who Can and Cannot Use Mycoril Spray?

The eligibility for Mycoril Spray (Clotrimazole Topical Solution) is strictly defined by regulatory documents, distinguishing between permitted use, conditional use, and absolute contraindications.


Contraindicated Populations

Use is absolutely contraindicated in patients who have a known history of hypersensitivity or allergy to the active substance, Clotrimazole, or to any other medicine in the azole antifungal class.

Eligibility by Age Group and Physiological Status

Population Eligibility Status Regulatory Requirement
Adults and Adolescents Established General topical use is permitted.
Children Established ge 2 Years Safety and effectiveness are established for children aged two years and older.
Children < 2 Years Not Recommended (Self-Medication) Use in children under two years is not recommended without professional medical consultation.
Pregnant Women Conditional Use Permitted, but only under the direction or supervision of a physician.
Nursing Mothers Conditional Use Permitted, but if applied to the breast area, the area must be washed before feeding due to minimal systemic absorption.

Use Restrictions

The product is not eligible for application to the eyes (ophthalmic use). Furthermore, topical Clotrimazole is officially documented as not effective for certain localized conditions, specifically fungal nail infections (Onychomycosis) or infections of the scalp.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Mycoril Spray (Topical Clotrimazole) based primarily on its minimal systemic absorption. This characteristic limits the potential for systemic drug-drug interactions observed with oral medications.


Pharmacokinetic and Systemic Interactions

The topical formulation of Clotrimazole results in plasma concentrations that are too low to cause clinically relevant inhibition or induction of cytochrome P450 enzymes. Consequently, regulatory sources confirm an absence of documented systemic pharmacokinetic interactions, including those mediated by metabolic enzymes or drug transporters. No systemic medicinal products are officially listed as contraindicated, and no timing separation requirements exist for oral medications due to interactions with this spray.


Local Pharmacodynamic Interactions

The only specific interaction pattern documented is a local pharmacodynamic antagonism that occurs at the site of application. Co-application of Mycoril Spray with topical Polyene Antifungals (such as Nystatin or Amphotericin B) to the same treatment area may result in antagonism. This interaction is officially described as leading to a reduction in the overall antifungal efficacy of both products locally. Regulatory guidelines therefore restrict the simultaneous application of these specific categories of topical antifungals.

Mechanism of Action

The action of Mycoril Spray's active ingredient, Clotrimazole, is based on the disruption of essential fungal cell components, resulting in the organism's death or growth inhibition.


Molecular Blockade of Ergosterol Biosynthesis

Clotrimazole functions as a specific inhibitor of the fungal enzyme Lanosterol 14-alpha-demethylase (CYP51). By binding to this enzyme, the drug halts the critical conversion of lanosterol into ergosterol, the primary sterol component needed to maintain the fungal cell membrane.


Catastrophic Failure of the Fungal Cell Membrane

This enzymatic blockade triggers a mechanistic cascade defined by two events: depletion of ergosterol and the toxic accumulation of abnormal sterols. These structural changes profoundly disorganize the cell membrane. This cascade leads to the failure of the membrane's permeability barrier, resulting in the leakage of essential intracellular contents and the subsequent death or growth arrest of the pathogen.


Localized Pathogen Mechanism Termination

The cellular destruction caused by the preceding steps results in the death or growth arrest of the causative fungal organism at the site of application. The termination of pathogen viability removes the biological stimulus that drives the local physiological response.

Dosage and Administration Information

How to Use Mycoril Spray

Mycoril Spray is an Azole Antifungal, or antimycotic, that is formulated as a 1% topical solution for application directly to the skin. The official administration route is topical and is strictly for external use, avoiding contact with mucosal surfaces, eyes, nose, and mouth, as directed by official prescribing information.


Official Administration Protocol

The usage protocol for the topical solution is standardized across regulatory documentation. The product should be applied twice a day, typically once in the morning and once in the evening. The dose is defined by coverage, requiring a sufficient amount of the spray to create a thin layer that covers the entire affected skin area, including a small margin of surrounding healthy skin.

Procedural Requirement Instruction as per Official Labeling
Preparation The affected skin area must be cleaned and thoroughly dried before each application.
Frequency Applied twice daily (every 12 hours) to maintain consistent action.
Dosing Rule Cover the affected area and the immediate surrounding skin.
Duration The full course of treatment, typically two to four weeks, must be completed.

The duration of treatment is fixed to help achieve full resolution. Official instructions mandate that use should be continued for a period after symptoms like redness and discomfort have visibly resolved. For instance, treatment for conditions like athlete's foot often requires application for the entire four-week period. If a scheduled application is missed, it should be applied as soon as it is remembered, but the patient should not apply extra product at the next scheduled time. No dose adjustments are typically required for older adult or pediatric patients, as systemic absorption from the topical route is minimal.

Recent Clinical Evidence

Research evidence / Overview of studies for Mycoril Spray

The overview of studies for Mycoril Spray focuses on the clinical evaluation of its active ingredient, Clotrimazole, as reported in regulatory and peer-reviewed scientific sources. The research primarily examines the clinical evaluation of the compound when applied topically to the skin for superficial fungal and yeast infections.


Evidence for Use in Tinea Pedis (Athlete's Foot) and Tinea Cruris (Jock Itch)

Research on the use of topical Clotrimazole for conditions like Tinea Pedis and Tinea Cruris largely consists of Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time compared to a non-active solution (vehicle) or another existing treatment. Researchers examined outcomes related to physical discomfort, such as the degree of redness, scaling, and itching, alongside mycological cure, which is the laboratory confirmation that the fungi have been eliminated.

It is noted that many studies exploring these types of infections have follow-up durations that were limited to the short-term treatment period. Therefore, long-term effects are not fully established, and there is limited information for long-term outcomes regarding how often the infection may recur after treatment is completed.


Evidence for Use in Tinea Corporis (Ringworm) and Cutaneous Candidiasis

The evidence for Tinea Corporis (Ringworm) is also rooted in clinical trials that were evaluated in populations presenting with the characteristic ring-shaped rash. Studies explored how the affected areas evolved over defined time intervals. For Cutaneous Candidiasis (yeast infections of the skin), the research was observed in a wider range of patients, including adults and also children and infants. Studies examined the proportion of participants achieving both clinical and mycological clearance, focusing on outcomes linked to inflammatory or irritative states.

However, the evidence base for Cutaneous Candidiasis is limited because the condition can present in many different ways across the body, which leads to evidence quality that varies across studies due to the wide range of populations and conditions included.


Comparison of Available Research and Evidence Quality

The research base for topical Clotrimazole has been a focus of research for several decades, and this is reflected in the compound. The main types of evidence are controlled clinical trials and regulatory summaries. These studies were studied for their potential to cause a change in symptom intensity or variability compared to a placebo or alternative compound.


Evidence in Special Populations

The research has examined the use of this antifungal in some specific populations, though data for certain groups remain insufficient. Studies have observed outcomes related to physical discomfort in children generally older than three years. Additionally, the ingredient was observed in some studies during pregnancy, but data remain insufficient for dedicated studies in this group.

Comparative evidence is lacking for many specific sub-groups of patients. The general evidence base does not determine whether an individual will respond similarly and results apply only to the populations studied in the key regulatory trials.

Frequently Asked Questions (FAQ)

Common questions about Mycoril Spray (FAQ)


Q: Is Mycoril Spray the same kind of medicine as X drug (a fictional similar drug)?

A: Regulatory documents classify the active ingredient, Clotrimazole, as an Azole Antifungal (antimycotic). This classification places it within a specific family of medicines recognized for working against fungal organisms. The official product information establishes this core classification, which allows for descriptive comparison with other drugs in the same class.


Q: Are there common ingredients in Mycoril Spray that cause allergies?

A: The official product information lists all components of Mycoril Spray, including the active ingredient and other inactive components (excipients). According to regulatory documents, the product is contraindicated if a person has a known allergy or hypersensitivity to the active ingredient or any other excipient in the product's official composition. This is the primary safety constraint regarding allergies.


Q: Does Mycoril Spray contain any steroids?

A: Official regulatory documents define the composition of Mycoril Spray. The product is described as containing only the antifungal active ingredient, Clotrimazole, along with other inactive components. It is not listed as a combination product with steroids in its official formulation.


Q: How quickly should I expect to notice any effect from Mycoril Spray?

A: Studies and official information indicate that while the full course of treatment may require several weeks, clinical evaluations have examined outcomes showing changes in physical discomfort and symptoms over the initial days or first week of use. Official usage protocols state that application should be continued for the full duration described, even after symptoms clear.


Q: Do I need a prescription to get Mycoril Spray in most places?

A: The drug's regulatory status, which determines whether it is legally classified as an over-the-counter (OTC) medicine or a prescription-only medicine (POM), is defined by national health agencies. This classification dictates whether the medicine can be obtained without consulting a physician, and its status may vary depending on the country or region.


Q: Can Mycoril Spray cause drowsiness or affect driving?

A: Regulatory information indicates that the active ingredient's systemic absorption is minimal when applied to the skin. Therefore, Mycoril Spray is not expected to affect the central nervous system, including the ability to drive or operate machinery, as described in official documents.


Q: What happens if I accidentally swallow some of the spray?

A: Accidental swallowing of the spray is addressed in the official product information. Regulatory documents describe that such an event is unlikely to cause harm due to the low concentration of the active ingredient and poor systemic absorption from the topical formulation.


Q: Does Mycoril Spray contain alcohol or preservatives?

A: The full list of excipients, which are the inactive components used in the solution base, is detailed in the official regulatory documents. This list details all ingredients, including any specific alcohol or preservatives that are part of the product's composition.


Q: How long does the effect of Mycoril Spray usually last after use?

A: The duration of the antifungal effect is supported by the twice-daily application schedule described in the usage protocol. Regulatory documents mention that when the active ingredient is absorbed into the bloodstream, it has an elimination half-life of approximately 3 to 5 hours. This data supports the need for repeated application to maintain concentration at the treatment site.


Q: Do regulatory agencies classify Mycoril Spray as a high-risk medication?

A: Official safety profiles emphasize that the risks associated with Mycoril Spray are predominantly local skin reactions at the application site, such as stinging or irritation. While rare, serious systemic immune events like anaphylaxis are listed, the primary safety structure reflects a low level of systemic concern due to minimal absorption.


Q: Is Mycoril Spray likely to affect results of medical lab tests?

A: The minimal systemic absorption of the active ingredient into the bloodstream makes it unlikely to affect the results of medical laboratory tests, according to regulatory sources.


Q: Can I use other topical creams or sprays at the same time as Mycoril Spray?

A: Official documents warn of a local antagonism if Mycoril Spray is used at the same site as other specific topical antifungal medications, such as Polyene Antifungals (like Nystatin). This interaction can lead to a reduction in efficacy of both products locally. The safety or interaction with non-antifungal topical products is not specifically detailed.


Q: How is the safety of Mycoril Spray monitored after it is approved?

A: Regulatory authorities require the manufacturer and healthcare professionals to report any suspected adverse reactions as part of the ongoing, long-term surveillance of the product.


Q: Is Mycoril Spray known to have any withdrawal effects when stopped?

A: Official regulatory information, including the detailed sections on adverse reactions, do not list any documented withdrawal effects associated with discontinuing the use of Mycoril Spray.


Q: Does Mycoril Spray affect my immune system generally?

A: Regulatory documents list rare, serious systemic events that involve the immune system, such as hypersensitivity or anaphylactic reactions, which are allergic in nature. The product information does not discuss a general, non-allergic modulating effect on the immune system.


Q: Is there information about Mycoril Spray use in people with kidney problems?

A: Due to the minimal systemic absorption from the topical route, regulatory sources state that dose adjustments are typically not required for patients with kidney problems. This reflects that the drug primarily acts locally at the site of application.


Q: What are the descriptive usage conditions for Mycoril Spray in people with liver problems?

A: Similar to kidney function, the minimal systemic absorption of Mycoril Spray means that the drug does not rely significantly on the liver for processing. Regulatory sources state that dose adjustments are typically not required for patients with liver problems.


Q: Does using Mycoril Spray make you more sensitive to sun exposure?

A: Official safety documents list potential adverse reactions associated with drug use. Photosensitivity (increased sensitivity to sunlight) is not listed as a known adverse reaction associated with the use of Mycoril Spray.


Q: Does the spray contain gluten or lactose, for those with intolerances?

A: The complete list of inactive ingredients (excipients), which would include information about the presence of common allergens or intolerances like lactose or gluten, is detailed in the official composition found in regulatory documents.

--ENSURE --

Q: Does Mycoril Spray have any specific warnings for people with heart conditions?

A: Official documents contain no specific warnings or precautions related to the use of Mycoril Spray for patients with heart conditions. This is consistent with its minimal systemic absorption.


Q: Can I use Mycoril Spray if I have a history of asthma?

A: Official regulatory documents list a known hypersensitivity to the drug or its components as the primary contraindication for use. However, the product information does not list asthma as a specific restriction or contraindication for Mycoril Spray.

How should Mycoril Spray be stored and disposed of?

How to Store and Dispose of Mycoril Spray?

Regulatory documents specify strict conditions for storing Mycoril Spray (Clotrimazole) to maintain its stability. The product must be stored at room temperature, generally not above 25°C (77°F), and kept from freezing.

Storage Requirements

The medicine must be protected from excessive heat, moisture, and direct light. It is required to be stored out of the sight and reach of children and remain in the original container, which must be kept tightly closed.

Disposal

Do not dispose of this medication via wastewater or household waste. Any unused or expired product must be managed in accordance with local requirements. Consult a pharmacist for guidance on proper disposal procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Mycoril Spray found in:

A-Z Index: